Interferon lambda concentrations in nasal lining fluid fell in or above the predicted therapeutic range with a nasally ...

Background： Sepsis is a complex clinical syndrome characterized by dysregulated immune responses, systemic inflammation, and ...

Nadofaragene firadenovec is the first and only non-replicating gene therapy administered intravesically, and it is already approved and launched in the US This represents the first filing ...

Autoimmune hepatitis (AIH) is a severe immune-mediated liver disease with limited treatment options beyond immunosuppressants, which carry significant ...

CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the efficacy and safety of the company's anti-GDF ...

England’s goal to eradicate bovine tuberculosis (TB) by 2038 remains alive – but only just. In the past decade, 274,000 ...

Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDTCompany ParticipantsPriya Singhal - Executive ...

IMNN-001 continues to show a favorable safety profile.

Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 First disclosure of a novel mechanism of action for ...

In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the potential of tumor necrosis factor-like ligand 1A inhibitors in treating inflammatory bowel disease. In a Healio video exclusive, ...